Stephens & Co. analyst Jacob Johnson maintains Bio-Techne (NASDAQ:TECH) with a Overweight, adjusts price target to $105 – 4-for-1 stock split.
Deutsche Bank Initiates Coverage On Avient with Buy Rating, Announces Price Target of $40
Deutsche Bank analyst David Huang initiates coverage on Avient (NYSE:AVNT) with a Buy rating and announces Price Target of $40.